ישראל - עברית - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - bazedoxifene acetate; estrogens conjugated - טבליות בשחרור מושהה - bazedoxifene acetate 20 mg; estrogens conjugated 0.45 mg - conjugated estrogens and bazedoxifene

ישראל - עברית - Ministry of Health

neopharm ltd - bazedoxifene as acetate 20 mg - coated tablets - bazedoxifene - conbriza is indicated for the treatment of postmenopausal osteoporosis in women at increased risk of fracture. a significant reduction in the incidence of vertebral fractures has been demonstrated; efficacy on hip fractures has not been established. when determining the choice of conbriza or other therapies, including oestrogens, for an individual postmenopausal woman, consideration should be given to menopausal symptoms, effects on uterine and breast tissues, and cardiovascular risks and benefit

ישראל - עברית - Ministry of Health

salomon,levin & elstein ltd - estrogens conjugated 0.3 mg - tablets - conjugated estrogens - estrogenus tablets are indicated in the:1. treatment of moderate to severe vasomotor symptoms associated with menopause. 2. treatment of moderate to severe vaginal dryness and pain with intercourse, symptoms of vulvar and vaginal atrophy, associated with menopause. when prescribing solely for the treatment of moderate to severe vaginal dryness and pain with intercourse, topical vaginal products should be considered.

ישראל - עברית - Ministry of Health

salomon,levin & elstein ltd - estrogens conjugated 0.45 mg - tablets - conjugated estrogens - estrogenus tablets are indicated in the:treatment of moderate to severe vasomotor symptoms associated with menopause.

ישראל - עברית - Ministry of Health

salomon,levin & elstein ltd - estrogens conjugated 0.625 mg - tablets - conjugated estrogens - estrogenus tablets are indicated in the:treatment of moderate to severe vasomotor symptoms associated with menopause.

ישראל - עברית - Ministry of Health

salomon,levin & elstein ltd - estrogens conjugated 0.9 mg - tablets - conjugated estrogens - estrogenus tablets are indicated in the:treatment of moderate to severe vasomotor symptoms associated with menopause.

ישראל - עברית - Ministry of Health

salomon,levin & elstein ltd - estrogens conjugated 1.25 mg - tablets - conjugated estrogens - estrogenus tablets are indicated in the:treatment of moderate to severe vasomotor symptoms associated with menopause.

ישראל - עברית - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - exemestane - טבליות מצופות - exemestane 25 mg - exemestane - exemestane - aromasin is indicated for the treatment of advanced breast cancer (abc) in women with natural or induced postmenopausal status whose disease has progressed following anti-oestrogen therapy alone. aromasin is also indicated for the treatment of postmenopausal women with abc whose disease has progressed following multiple hormonal therapies. aromasin is indicated for the adjuvant treatment of postmenopausal women with oestrogen receptor positive invasive early breas cancer following 2-3 years of initial adjuvant tamoxifen therapy.

ישראל - עברית - Ministry of Health

astra zeneca (israel) ltd - fulvestrant - תמיסה להזרקה - fulvestrant 250 mg / 5 ml - fulvestrant - fulvestrant - faslodex is indicated for the treatment of postmenopausal women with oestrogen receptor positive, locally advanced or metastatic breast cancer for disease relapse on or after adjuvant antioestrogen therapy or disease progression on therapy with an antioestrogen.

ישראל - עברית - Ministry of Health

astra zeneca (israel) ltd - fulvestrant - תמיסה להזרקה - fulvestrant 250 mg / 5 ml - fulvestrant - fulvestrant - faslodex is indicated for the treatment of postmenopausal women with oestrogen receptor positive, locally advanced or metastatic breast cancer for disease relapse on or after adjuvant antioestrogen therapy or disease progression on therapy with an antioestrogen.06/06/2010 בקשה לשינוי משטר מינון the recommended dose is 500 mg at intervals of one month, with an additional 500 mg dose given two weeks after the initial dose.